DexCom (DXCM) Stock Price, News & Analysis

DexCom logo
$80.19 -2.33 (-2.82%)
Closing price 04:00 PM Eastern
Extended Trading
$79.18 -1.01 (-1.26%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About DexCom Stock (NASDAQ:DXCM)

Advanced

Key Stats

Today's Range
$79.17
▼
$83.09
50-Day Range
$77.94
▼
$89.53
52-Week Range
$56.72
▼
$92.59
Volume
4.47 million shs
Average Volume
5.01 million shs
Market Capitalization
$29.91 billion
P/E Ratio
30.91
Dividend Yield
N/A
Price Target
$95.50
Consensus Rating
Buy

Company Overview

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions.

The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin. Its CGM technology can connect with certain insulin pumps and other digital health tools.

Founded in 1999 and headquartered in San Diego, California, DexCom serves customers in the United States and international markets. The company has focused on expanding access to glucose monitoring through wearable devices and connected health technology.

AI Generated. May Contain Errors.

DexCom Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

DXCM MarketRank™: 
3.69577117832 of 5 stars

DexCom scored higher than 74% of companies evaluated by MarketBeat, and ranked 143rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DexCom has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 24 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    DexCom has a consensus price target of $95.50, representing about 19.1% upside from its current price of $80.19.

  • Amount of Analyst Coverage

    DexCom has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about DexCom's stock forecast and price target.
  • Earnings Growth

    Earnings for DexCom are expected to grow by 14.93% in the coming year, from $2.68 to $3.08 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DexCom is 30.91, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.64.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DexCom is 30.91, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.77.

  • Price to Earnings Growth Ratio

    DexCom has a PEG Ratio of 1.36. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    DexCom has a P/B Ratio of 11.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.28% of the float of DexCom has been sold short.
  • Short Interest Ratio / Days to Cover

    DexCom has a short interest ratio ("days to cover") of 2.81, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in DexCom has recently increased by 1.55%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    DexCom does not currently pay a dividend.

  • Dividend Growth

    DexCom does not have a long track record of dividend growth.

  • News Sentiment

    DexCom has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for DexCom this week, compared to 9 articles on an average week.
  • Search Interest

    Only 7 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,920,193.00 in company stock.

  • Percentage Held by Insiders

    0.28% of the stock of DexCom is held by insiders.

  • Percentage Held by Institutions

    97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about DexCom's insider trading history.
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DXCM Stock News Headlines

DexCom Opens First Manufacturing Facility in Ireland
DexCom, Inc. Opens Manufacturing Facility in Athenry, County Galway
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

DXCM Stock Analysis - Frequently Asked Questions

DexCom's stock was trading at $66.37 at the beginning of the year. Since then, DXCM stock has increased by 20.8% and is now trading at $80.19.

DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Thursday, October, 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.68 by $0.05. DexCom's revenue was up 11.1% on a year-over-year basis.
Read the conference call transcript
.

DexCom's stock split before market open on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were issued to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom subsidiaries include these companies: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more.

DexCom's top institutional investors include Stephens Investment Management Group LLC (0.34%), First Trust Advisors LP (0.27%), Sumitomo Mitsui Trust Group Inc. (0.24%) and Healthcare of Ontario Pension Plan Trust Fund (0.22%). Insiders that own company stock include Jacob Steven Leach, Kevin R Sayer, Jereme M Sylvain, Steven Robert Pacelli, Sadie Stern, Michael Jon Brown, Jon Coleman, Jon Coleman, Steven R Altman, Mark G Foletta, Matthew Vincent Dolan, Richard Alexander Collins, Nicholas Augustinos, Bridgette P Heller and Kyle Malady.
View institutional ownership trends
.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Netflix (NFLX), Shopify (SHOP) and Salesforce (CRM).

Company Calendar

Last Earnings
10/29/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:DXCM
CIK
1093557
Employees
11,000
Year Founded
1999

Price Target and Rating

High Price Target
$120.00
Low Price Target
$65.00
Potential Upside/Downside
+19.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
28 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.55
Trailing P/E Ratio
30.91
Forward P/E Ratio
26.04
P/E Growth
1.36
Net Income
$836.30 million
Net Margins
19.42%
Pretax Margin
24.73%
Return on Equity
37.77%
Return on Assets
15.98%

Debt

Debt-to-Equity Ratio
0.49
Current Ratio
1.74
Quick Ratio
1.40

Sales & Book Value

Annual Sales
$4.66 billion
Price / Sales
6.42
Cash Flow
$2.69 per share
Price / Cash Flow
29.80
Book Value
$6.80 per share
Price / Book
11.79

Miscellaneous

Outstanding Shares
372,950,000
Free Float
371,907,000
Market Cap
$29.91 billion
Optionable
Optionable
Beta
1.45

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:DXCM) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners